Mayo Clinic will present plasma ceramide results at ACC 2017

The CERAM test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.

Mayo Clinic conducted a trial with 499 patients to evaluate the value of the plasma ceramide test, developed by Zora Biosciences.

The study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart’s arteries.

The results of the Mayo Clinic research will be presented at the American College of Cardiology’s 66th Annual Scientific Session.